Bellicum Pharmaceuticals (BLCM) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Environmental Protection Extreme Weather Materials Nature Offset Package Packaging Pandemic Raw Materials Recycling Toxic Waste Water Access African American Asian Benefits Black California Consumer Privacy Act Charity Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Death Demographic Disability Diversity Drug Pricing Employee Employee Retention Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injury Labor Standards Latinx LGBTQ Perquisites Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Workforce Anti-corruption Assessment Assurance Attorneys General Audit Bonus Bribe Bribery Classified Clawback Commitment Controversy Corporate Governance Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Other Public Company Boards Oversee Oversight Perquisite Plaintiff Proxy Contest Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Special Meeting Strategy Targets Tax Tax Gross Up Transparency Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final voting results with respect to each matter:

Proposal 1. Election of Directors

The Company’s stockholders elected the person listed below as a Class II Director, to serve until the Company’s 2025 annual meeting of stockholders and until their successor is duly elected and qualified. The final voting results are as follows:

Name of Director Nominee	Votes For	Votes Withheld	Broker Non-Votes


Judith Klimovsky, M.D.	1,723,047	152,813	2,985,038

Proposal 2. Approval of the Plan Amendment

The Company’s stockholders approved the Amended 2019 Plan. The final voting results were as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes


1,617,290	255,718	2,852	2,985,038

Proposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Company’s Board of Directors to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The final voting results are as follows:



Votes For	Votes Against	Abstentions
4,480,357	135,697	244,844

Proposal 4. Advisory Vote on Executive Compensation

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows:

Votes For	Votes Against	Abstentions	Broker Non-Votes


1,569,503	292,255	14,102	2,985,038

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits



Exhibit Number			Description

10.1			Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, as amended.

104			Cover Page Interactive Data File (embedded within the Inline XBRL document)